Skip to main navigation Skip to search Skip to main content

Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((S)-2-nitro-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824)

  • Joseph Cherian
  • , Inhee Choi
  • , Amit Nayyar
  • , Ujjini H. Manjunatha
  • , Tathagata Mukherjee
  • , Yong Sok Lee
  • , Helena I. Boshoff
  • , Ramandeep Singh
  • , Young Hwan Ha
  • , Michael Goodwin
  • , Suresh B. Lakshminarayana
  • , Pornwaratt Niyomrattanakit
  • , Jan Jiricek
  • , Sindhu Ravindran
  • , Thomas Dick
  • , Thomas H. Keller
  • , Veronique Dartois
  • , Clifton E. Barry
  • Novartis
  • Agency for Science, Technology and Research, Singapore
  • National Institutes of Health
  • Translational Health Science and Technology Institute
  • Curachem, Inc.

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

The (S)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2, 1-b][1,3]oxazine named PA-824 (1) has demonstrated antitubercular activity in vitro and in animal models and is currently in clinical trials. We synthesized derivatives at three positions of the 4-(trifluoromethoxy)benzylamino tail, and these were tested for whole-cell activity against both replicating and nonreplicating Mycobacterium tuberculosis (Mtb). In addition, we determined their kinetic parameters as substrates of the deazaflavin-dependent nitroreductase (Ddn) from Mtb that reductively activates these pro-drugs. These studies yielded multiple compounds with 40 nM aerobic whole cell activity and 1.6 μM anaerobic whole cell activity: 10-fold improvements over both characteristics from the parent molecule. Some of these compounds exhibited enhanced solubility with acceptable stability to microsomal and in vivo metabolism. Analysis of the conformational preferences of these analogues using quantum chemistry suggests a preference for a pseudoequatorial orientation of the linker and lipophilic tail.

Original languageEnglish
Pages (from-to)5639-5659
Number of pages21
JournalJournal of Medicinal Chemistry
Volume54
Issue number16
DOIs
StatePublished - 25 Aug 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((S)-2-nitro-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824)'. Together they form a unique fingerprint.

Cite this